改变生活方式的糖尿病前期患者与口服降糖药患者HbA1c水平的比较研究

IF 2 4区 医学 Q3 PHARMACOLOGY & PHARMACY
Raj Kumar Thapa, Kushal Shrestha, Kanchan K. C., Sirapa Maharjan, Shashwot Sedhain, Reshu B. K., Sitaram Khadka
{"title":"改变生活方式的糖尿病前期患者与口服降糖药患者HbA1c水平的比较研究","authors":"Raj Kumar Thapa,&nbsp;Kushal Shrestha,&nbsp;Kanchan K. C.,&nbsp;Sirapa Maharjan,&nbsp;Shashwot Sedhain,&nbsp;Reshu B. K.,&nbsp;Sitaram Khadka","doi":"10.1155/jcpt/9947273","DOIUrl":null,"url":null,"abstract":"<div>\n <p><b>Background:</b> Lifestyle modifications are the cornerstone of prediabetes management, aiming to prevent or delay progression to diabetes. In addition to lifestyle interventions, pharmacologic treatment with oral hypoglycemic agents (OHAs), particularly metformin, is frequently considered.</p>\n <p><b>Objectives:</b> The objective of this study was to identify optimal strategies for the management of prediabetes in low- and middle-income countries (LMICs) like Nepal.</p>\n <p><b>Methods:</b> A comparative experimental study was conducted to assess the effects of lifestyle modification and treatment with OHA separately in prediabetic patients (16 per group). The lifestyle modification group (Group A) received structured counseling on dietary modifications and physical activity, and the OHA group (Group B) was prescribed metformin. Baseline parameters were recorded for all participants, and blood pressure and HbA1c levels were reassessed at 90 days to determine changes from the baseline.</p>\n <p><b>Results:</b> Significant reduction in HbA1c was observed for both the OHA group (<i>p</i> = 0.0034) and the lifestyle modification group (<i>p</i> &lt; 0.001). The lifestyle modification group achieved significantly greater reductions in HbA1c compared with the OHA group (<i>p</i> = 0.0002).</p>\n <p><b>Conclusions:</b> Lifestyle modification and pharmacological therapy with metformin can lead to a significant decrease in HbA1c levels in the prediabetic population as a sole intervention. Lifestyle modification resulting in greater reduction could be a sustainable and cost-effective alternative, particularly in LMICs like Nepal.</p>\n </div>","PeriodicalId":15381,"journal":{"name":"Journal of Clinical Pharmacy and Therapeutics","volume":"2025 1","pages":""},"PeriodicalIF":2.0000,"publicationDate":"2025-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/jcpt/9947273","citationCount":"0","resultStr":"{\"title\":\"A Comparative Study of the HbA1c Level in Prediabetic Patients With Lifestyle Modification Versus Oral Hypoglycemic Agents\",\"authors\":\"Raj Kumar Thapa,&nbsp;Kushal Shrestha,&nbsp;Kanchan K. C.,&nbsp;Sirapa Maharjan,&nbsp;Shashwot Sedhain,&nbsp;Reshu B. K.,&nbsp;Sitaram Khadka\",\"doi\":\"10.1155/jcpt/9947273\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n <p><b>Background:</b> Lifestyle modifications are the cornerstone of prediabetes management, aiming to prevent or delay progression to diabetes. In addition to lifestyle interventions, pharmacologic treatment with oral hypoglycemic agents (OHAs), particularly metformin, is frequently considered.</p>\\n <p><b>Objectives:</b> The objective of this study was to identify optimal strategies for the management of prediabetes in low- and middle-income countries (LMICs) like Nepal.</p>\\n <p><b>Methods:</b> A comparative experimental study was conducted to assess the effects of lifestyle modification and treatment with OHA separately in prediabetic patients (16 per group). The lifestyle modification group (Group A) received structured counseling on dietary modifications and physical activity, and the OHA group (Group B) was prescribed metformin. Baseline parameters were recorded for all participants, and blood pressure and HbA1c levels were reassessed at 90 days to determine changes from the baseline.</p>\\n <p><b>Results:</b> Significant reduction in HbA1c was observed for both the OHA group (<i>p</i> = 0.0034) and the lifestyle modification group (<i>p</i> &lt; 0.001). The lifestyle modification group achieved significantly greater reductions in HbA1c compared with the OHA group (<i>p</i> = 0.0002).</p>\\n <p><b>Conclusions:</b> Lifestyle modification and pharmacological therapy with metformin can lead to a significant decrease in HbA1c levels in the prediabetic population as a sole intervention. Lifestyle modification resulting in greater reduction could be a sustainable and cost-effective alternative, particularly in LMICs like Nepal.</p>\\n </div>\",\"PeriodicalId\":15381,\"journal\":{\"name\":\"Journal of Clinical Pharmacy and Therapeutics\",\"volume\":\"2025 1\",\"pages\":\"\"},\"PeriodicalIF\":2.0000,\"publicationDate\":\"2025-07-21\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1155/jcpt/9947273\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Clinical Pharmacy and Therapeutics\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1155/jcpt/9947273\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Clinical Pharmacy and Therapeutics","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1155/jcpt/9947273","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

摘要

背景:改变生活方式是糖尿病前期管理的基础,旨在预防或延缓糖尿病的进展。除了生活方式干预,口服降糖药(OHAs)的药物治疗,特别是二甲双胍,经常被考虑。目的:本研究的目的是确定尼泊尔等中低收入国家(LMICs)糖尿病前期管理的最佳策略。方法:对糖尿病前期患者(每组16例)分别进行生活方式改变和OHA治疗的效果对比实验研究。生活方式改变组(A组)接受有关饮食改变和体育活动的结构化咨询,OHA组(B组)开二甲双胍。记录所有参与者的基线参数,并在90天重新评估血压和HbA1c水平,以确定基线的变化。结果:在OHA组(p = 0.0034)和生活方式改变组(p <;0.001)。与OHA组相比,生活方式改变组的HbA1c显著降低(p = 0.0002)。结论:生活方式改变和二甲双胍药物治疗作为唯一干预措施可显著降低糖尿病前期人群的HbA1c水平。改变生活方式导致更大的减少可能是一种可持续和具有成本效益的替代方案,特别是在尼泊尔这样的中低收入国家。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

A Comparative Study of the HbA1c Level in Prediabetic Patients With Lifestyle Modification Versus Oral Hypoglycemic Agents

A Comparative Study of the HbA1c Level in Prediabetic Patients With Lifestyle Modification Versus Oral Hypoglycemic Agents

Background: Lifestyle modifications are the cornerstone of prediabetes management, aiming to prevent or delay progression to diabetes. In addition to lifestyle interventions, pharmacologic treatment with oral hypoglycemic agents (OHAs), particularly metformin, is frequently considered.

Objectives: The objective of this study was to identify optimal strategies for the management of prediabetes in low- and middle-income countries (LMICs) like Nepal.

Methods: A comparative experimental study was conducted to assess the effects of lifestyle modification and treatment with OHA separately in prediabetic patients (16 per group). The lifestyle modification group (Group A) received structured counseling on dietary modifications and physical activity, and the OHA group (Group B) was prescribed metformin. Baseline parameters were recorded for all participants, and blood pressure and HbA1c levels were reassessed at 90 days to determine changes from the baseline.

Results: Significant reduction in HbA1c was observed for both the OHA group (p = 0.0034) and the lifestyle modification group (p < 0.001). The lifestyle modification group achieved significantly greater reductions in HbA1c compared with the OHA group (p = 0.0002).

Conclusions: Lifestyle modification and pharmacological therapy with metformin can lead to a significant decrease in HbA1c levels in the prediabetic population as a sole intervention. Lifestyle modification resulting in greater reduction could be a sustainable and cost-effective alternative, particularly in LMICs like Nepal.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
4.10
自引率
5.00%
发文量
226
审稿时长
6 months
期刊介绍: The Journal of Clinical Pharmacy and Therapeutics provides a forum for clinicians, pharmacists and pharmacologists to explore and report on issues of common interest. Reports and commentaries on current issues in medical and pharmaceutical practice are encouraged. Papers on evidence-based clinical practice and multidisciplinary collaborative work are particularly welcome. Regular sections in the journal include: editorials, commentaries, reviews (including systematic overviews and meta-analyses), original research and reports, and book reviews. Its scope embraces all aspects of clinical drug development and therapeutics, including: Rational therapeutics Evidence-based practice Safety, cost-effectiveness and clinical efficacy of drugs Drug interactions Clinical impact of drug formulations Pharmacogenetics Personalised, stratified and translational medicine Clinical pharmacokinetics.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信